Looking to highlight a funding opportunity? Please send a brief description, link, and deadline to email@example.com
State & Federal Programs
The National Cancer Institute (NCI) announces the availability of a funding opportunity aimed at accelerating the development and commercialization of highly innovative technologies that improve molecular and/or cellular analysis of cancer with a significant likelihood for either overcoming persistent challenges or obstacles or opening entirely new fields for cancer research or clinical care. This Program Announcement complements the goals of the NCI's Innovative Molecular Analysis Technologies (IMAT) program by facilitating a path towards technology commercialization. Prior participation in the IMAT Program is not required for eligibility for this FOA. Applications are expected to indicate the significant attributes and advantages of the proposed technology over currently available technologies and conventional approaches. Click here to learn more.
Receipt Dates: May 28, 2014; November 4, 2014; May 27, 2015; November 4, 2015; May 27, 2016
Applications open March 23, 2015
Do you have a drug discovery concept? Are you a principal investigator affiliated with a U.S. or Canadian research institute, college or university? Are you excited about partnering with a leading pharmaceutical company to translate your novel science into a new medicine? If so, the Discovery Fast Track Challenge is for you.
Proposals due by April 9, 2015
The Alzheimer's Association, Alzheimer's Research UK, The Michael J. Fox Foundation and the Weston Brain Institute announce a collaborative Request for Applications to stimulate analyses across Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases toward, for example, biomarker discovery, assay standardization, genetic profiling, and imaging development. Recent evidence suggests substantial overlap between these diseases pathologically, but also, potentially, biologically. The program is designed to enable pilot research or proof-of-principle studies utilizing data from large biomarker studies. Proposed projects must use resources from at least one either AD or PD cohort such as the Alzheimer's Disease Neuroimaging Initiative or the Parkinson's Progression Markers Initiative. Data may come from investigator-chosen cohorts, including of other neurodegenerative disease patients. The program offers resources from a frontotemporal lobar dementia (FTLD) cohort study.
Deadline: May 1, 2015
The Harrington Scholar-Innovator award selection committee seeks specific types of projects and applicants that are most likely to accelerate medical discoveries that can benefit patients, including:
- Breakthrough discoveries deemed to have high potential impact or to address unmet medical needs
- Early discovery projects (identification of new targets and leads), new drugs, drug-development programs, biologics or drug-device combinations, particularly those supported by highly innovative science
- Translational or development-type studies not typically funded by basic science or discovery grants (NIH R01 or similar)
- Physician-scientists in need of assistance with practical problems related to product development
Deadline: No deadline; applications accepted anytime
One-year grants to jump start new ideas in PD research. The Rapid Response Innovation Awards (RRIA) program supports high-risk, high-reward projects with little-to-no existing preliminary data, but with potential to significantly impact our understanding of Parkinson’s disease. Moreover, this program is well-suited for early exploratory studies that may open the field up to new targets or pathways that may ultimately feed the early drug development pipeline for a treatment of PD.
There is no deadline to apply; submit an Expressions of Interest here.
DELSIA is an independent nonprofit venture philanthropy affiliate of the autism research and advocacy foundation Autism Speaks. DELSIA provides funds to for-profit partners to advance the development of products that address unmet medical and behavioral health needs of the autism community. It was created as an innovative funding vehicle with the goal of improving outcomes for individuals with autism spectrum disorder (ASD). DELSIA aims to do this by ensuring that scientific breakthroughs and technological advances are developed into products that improve health and quality of life for individuals with autism and their families. Our purpose is to transform lives by serving as a catalyst to facilitate and accelerate the delivery and availability of impactful products.